COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N3US
|
|||
Drug Name |
FA-613
|
|||
Synonyms |
6-bromo-2-(4-ethoxyphenyl)-4-quinolinecarboxylic acid
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN dihydroorotate dehydrogenase (DHODH) | Target Info | Inhibitor | [1] |
FA-613 exhibits low micromolar antiviral activity against SARS-Cov and MERS-Cov via interfering with the de novo pyrimidine biosynthesis pathway by targeting the dihydroorotate dehydrogenase. |
References | Top | |||
---|---|---|---|---|
1 | Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. J Gen Virol. 2017 May;98(5):946-954. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.